EX-CELL^® CD昆虫细胞培养基

The current status and future manufacturing of AAV-based gene therapies is discussed in this podcast transcript, including how to streamline large-scale manufacturing.

Minimize the complexities of cell and gene therapy production. Switch to upstream viral vector platforms to enhance scalability and simplify GMP manufacturing.

Upstream gene therapy optimization maximizes viral vector titers; partner with technology experts for HEK293, HEK293T, and Sf9 cell solutions.

This technical article breaks down the steps of upstream and downstream bioprocessing and formulation of virus-like particle vaccines.

针对病毒载体生产的转染解决方案采用悬浮细胞系、化学成分明确的培养基以及性能已得到证明的工艺。

A transfection-based solution to viral vector production using a suspension cell line, chemically defined medium, and a process with proven performance at scale.